SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0732 183X OR L773:1527 7755 "

Sökning: L773:0732 183X OR L773:1527 7755

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
871.
  •  
872.
  •  
873.
  •  
874.
  •  
875.
  • Whelan, Jeremy, et al. (författare)
  • High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma : Results of Euro-E.W.I.N.G.99 and Ewing-2008
  • 2018
  • Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X. ; 36:31, s. 3110-3119
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis >200 mL if unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year eventfree survival (EFS) was sought (hazard ratio [HR], 0.60). Results Between 2000 and 2015, 240 patients classified as high risk (median age, 17.1 years) were randomly assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat analysis, the risk of event was significantly decreased by BuMel comparedwith VAI: HR, 0.64 (95%CI, 0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0%(95% CI, 60.2%to 76.6%) versus 56.7%(95%CI, 47.6%to 65.4%) and 60.7%(95%CI, 51.1%to 69.6%) versus 47.1%(95%CI, 37.7% to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and 8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to 79.6%) and 64.5%(95%CI, 54.4% to 73.5%) versus 55.6%(95%CI, 45.8%to 65.1%). Results were consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after standard chemotherapy. Significantly more BuMel patients experienced severe acute toxicities from this course of chemotherapy compared with multiple VAI courses. Conclusion BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction in localized ES with predefined high-risk factors. For this group of patients, BuMel may be an important addition to the standard of care.
  •  
876.
  •  
877.
  •  
878.
  •  
879.
  •  
880.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (549)
konferensbidrag (339)
forskningsöversikt (8)
annan publikation (1)
Typ av innehåll
refereegranskat (466)
övrigt vetenskapligt (431)
Författare/redaktör
Bergh, J (36)
Glimelius, Bengt (32)
Bergh, JCS (24)
Hall, P (22)
Glimelius, B (22)
Hansson, J. (19)
visa fler...
Foukakis, T (17)
Jonsson, B (15)
Osterborg, A (14)
Mellstedt, H (14)
Czene, K (14)
Nahi, H (14)
Ringden, O (14)
Tandstad, T. (13)
Landgren, O (12)
Johansson, H (11)
Lindblom, A (11)
Kimby, E (11)
Bjorkholm, M (11)
Avall-Lundqvist, E (11)
Helgadottir, H (11)
Usmani, SZ (11)
Wilking, N (11)
Fernö, Mårten (10)
Hjorth, Lars (10)
Pukkala, E (10)
Holmberg, Lars (10)
Hatschek, T (10)
Eriksson, H (10)
Fornander, T (10)
Cohn-Cedermark, G (10)
Masucci, GV (10)
Lind, PA (10)
Brandberg, Y (10)
Malmström, Per (9)
Kogner, P (9)
Moreau, P (9)
Eklund, M (9)
Stattin, Pär (9)
Eriksson, Mikael (9)
Lambe, M (9)
Karlsson, Per, 1963 (9)
Plesner, T (9)
Gronberg, H (9)
Hellstrom, M (9)
Greil, R (9)
Yachnin, J (9)
Hellstrom-Lindberg, ... (9)
Goldhirsch, Aron (9)
Gelber, Richard D (9)
visa färre...
Lärosäte
Karolinska Institutet (619)
Uppsala universitet (133)
Lunds universitet (123)
Göteborgs universitet (60)
Umeå universitet (49)
Linköpings universitet (23)
visa fler...
Örebro universitet (16)
Kungliga Tekniska Högskolan (8)
Marie Cederschiöld högskola (3)
Högskolan Kristianstad (1)
Stockholms universitet (1)
Malmö universitet (1)
Linnéuniversitetet (1)
Högskolan Dalarna (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (897)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (302)
Naturvetenskap (2)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy